Ibuprofen, a traditional drug that may impact the course of COVID-19 new effective formulation in nebulizable solution by García Canclini, Néstor et al.
Contents lists available at ScienceDirect
Medical Hypotheses
journal homepage: www.elsevier.com/locate/mehy
Ibuprofen, a traditional drug that may impact the course of COVID-19 new
effective formulation in nebulizable solution
Néstor H. Garcíaa,⁎, Daniela J. Portaa, Roxana V. Alasinob,c, Sonia E. Muñoza,
Dante M. Beltramob,c
a Instituto de Investigaciones en Ciencias de la Salud—FCM (INICSA-CONICET), Córdoba C 5000, Argentina
b Centro de Excelencia en Productos y Procesos de Córdoba (CEPROCOR), Ministerio de Ciencia y Tecnología de Córdoba Pabellón CEPROCOR, Santa María de Punilla,
Córdoba CP 5164, Argentina
c Consejo Nacional de Investigaciones Científicas y Técnicas, CONICET, Godoy Cruz 2290, C1425FQB CABA, Argentina
A B S T R A C T
The traditional formulation of ibuprofen is poorly soluble in water, so the administered dose must be 10 times higher than the dose required for a therapeutic effect.
The development of a hydrosoluble form of ibuprofen can be a strategy to reach a high concentration in the lungs by using modern inhalation devices. Therefore, the
development of an inhalable formulation with high bioavailability in the lungs was the leitmotiv of our investigation. The hypertonic ibuprofen solution to be
nebulized (NIH) presents great relevant characteristics: bactericidal, virucidal, mucolytic and has a known anti-inflammatory property. Bactericidal and virucidal
effects are related to the physico-chemical properties of Na-ibuprofenate as an amphipathic molecule. It has the capability to insert into the bilayer membranes
destabilizing the structure, altering its biological properties and avoiding the duplication or infection. Our preliminary results indicate that the presence of this high
ionic strength solution reduces 10 times the amount of ibuprofen necessary to kill bacteria, but also the time to kill 1x106 bacteria, from 4 h (in its absence) to only
three minutes (in its presence). That was observed using Pseudomona aeruginosa, methicillin-resistant Staphylococcus aureus and Burkholderia cepacia. Also, “in vitro''
ibuprofen demonstrated virucidal activity against the so-called enveloped virus, a family that includes coronavirus strain (2019-nCoV). We observed too, the
markedly reduced local inflammation in the airways after administering NIH lays on its ability to inhibit the enzyme cyclooxygenase and to markedly diminish
reactive oxygen species (ROS). Other investigators also showed the importance of actin in the rapid spread of virus infection. Furthermore, reorganization of the actin
filaments is a key step in lung inflammation induced by systemic inflammatory responses caused by SARS-CoV-2. These findings suggest that the interaction between
actin proteins and S1 is involved in the 2019-nCoV infection and pathogenesis.
Consequently, the possibility of interfering in this interaction could represent a valid hypothesis for the development of promising therapeutic and prevention
strategies. In conclusion, we consider that treating people with COVID-19 with NIH may be beneficial and an opportunity to contribute for the current global health
emergency.
The importance of ibuprofen in the respiratory tract has been de-
scribed previously in children with pulmonary cystic fibrosis but be-
sides the beneficial effect observed in this scenario, it is not frequently
prescribed, and the main reason is the high dosage required to produce
the desired effect in the lungs.
The traditional formulation of ibuprofen is poorly soluble in water,
so the administered dose must be 10 times higher than the dose re-
quired for a therapeutic effect [1]. In this sense, the distribution rate of
currently available traditional dosage forms is limited, leading to poor
bioavailability from a high oral dosage [2]. The development of a hy-
drosoluble form of ibuprofen can be a strategy to reach a high con-
centration in the lungs by using modern inhalation devices, without the
potential systemic effects of high dosages. This approach would allow
us to deliver micro or nanometer sized particles to reach a large surface
area, such as the pulmonary alveolar. The other benefit of this size is
that particles from 0.5 to 3 µm are captured by macrophages through
phagocytosis, but not those < 0.25 µm [1]. Having a formulation with
these properties would lead to a high potential for the treatment of lung
infections, such as pulmonary cystic fibrosis, pneumonia, and bronch-
iectasis [19].
Therefore, the development of an inhalable formulation with high
bioavailability in the lungs was the leitmotiv of our investigation.
Considering the characteristics of available ibuprofen formulations,
a solution with hypertonic ibuprofeno solution to be nebulized (NIH)
was developed with great relevant characteristics: it is bactericidal,
virucidal, mucolytic and has a known anti-inflammatory property. This
formulation was developed for the treatment of serious lung conditions,
such as cystic pulmonary fibrosis, pneumonia and bronchiectasis, be-
cause complications due to opportunistic infections are of great im-
portance in these lung pathologies. Additionally, since administration
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via inhalation was decided, it overcomes the limitations of the currently
available administrative routes to achieve a better therapeutic action at
a very low dose [4].
From insoluble to soluble
Recently Irvine et al. [18] explained the challenge of ibuprofen
solubilization in water. These researchers describe the solubility of this
drug as the major problem. So, different technologies particle en-
gineering or crystallization were applied in improving formulation
strategies. Finally, an attempt has been made to improve the delivery of
this drug into the pulmonary route for achieving better therapeutic
action at a very low dose, thus overcoming the limitations of currently
available delivery routes. Nanotechnology is the science that recently
appeared to solve this problem. In this case, several strategies have
been developed; however, the appropriate delivery of ibuprofen to the
lung using nanocarriers such as liposomes, dendrimers, emulsions or
polymers has been achieved, because there is an inability to reach en-
ough lung deposit [3].
From anti-inflammatory to viricidal and bactericidal effect of
Ibuprofen
The bactericidal effect was possibly confounded with the anti-in-
flammatory effect initially. During the 80′s, Ibuprofen’s ability to limit
bacterial damage from “in vivo'' was evaluated [11–13]. In 1990 Kon-
stan et al. [14] studied Ibuprofen's ability to limit lung damage induced
by Pseudomonas infection in rats. This early report was the cornerstone
to investigate ibuprofen in lung diseases but focus on the anti-in-
flammatory properties. Later, preclinical and clinical studies demon-
strated the beneficial effect of high dose of ibuprofen. In 1995, Michael
W. Konstan et al. [2], showed that high doses of ibuprofen in oral form,
decreased the progression of lung disease in patients with cystic fibrosis
and mild lung disease. Consequently, Lands et al. [15] investigated the
safety and efficacy of oral high-dose ibuprofen in children with CF in a
randomized, multicenter, double-blind, placebo-controlled trial along
2 years. This study demonstrated that a slowdown in the predicted
impaired vital capacity was observed in patients on high-dose ibu-
profen. Collectively, these clinical trials document the benefits and re-
lative safety of long-term use of high-dose ibuprofen in pediatric CF
patients by attributing these benefits to the modulating properties of
neutrophils [15]. At the same time Elvers et al. [16] evaluated the effect
of ibuprofen on the “in vitro” growth of six bacterial strains, and ob-
served that ibuprofen inhibited the growth of Gram-positive species.
¿But how ibuprofen has an antibacterial activity? The bactericidal
and virucidal effects are related to the physico-chemical properties of
Na-ibuprofenate as an amphipathic molecule. It has the capability to
insert into the bilayer membranes destabilizing the structure, altering
its biological properties and avoiding the duplication or infection of
bacterias or viruses.
Interestingly, this interaction is strongly reinforced and stabilized in
the presence of a high ionic strength solution, such as hypertonic so-
dium chloride. The presence of this high ionic strength solution reduces
10 times the amount of ibuprofen necessary to kill bacteria, but also the
time to kill 1x106 bacteria, from 4 h (in its absence) to only three
minutes (in its presence). That was observed using Pseudomona aerugi-
nosa, methicillin-resistant Staphylococcus aureus and Burkholderia ce-
pacia. Other investigators have reported similar results [20]. But the
effect does not end here, also “in vitro'' ibuprofen demonstrated vir-
ucidal activity against the so-called enveloped virus, a family that in-
cludes coronavirus strain (2019-nCoV) (Table 1).
Using an “in silico'' approach, Ibuprofen has been predicted as an
entry inhibitor of Ebola virus [5]. This prediction has then been ex-
perimentally confirmed [6,7], showing that Ibuprofen reduced 50% of
virus title in Vero cells. This virucidal effect has also been reported “in
vitro'' for Zika virus (ZIKV), where Ibuprofen plunged AXL expression, a
ZIKV entry cofactor. This data highlights the worth of drugs with a high
safety profile, which may even be indicated during pregnancy, to pre-
vent ZiKV infection. Although by different mechanisms, clear viral re-
plication regulatory effects have also been shown “in vitro'' and in
humans for other viruses like HSV-1, HSV-2, rotavirus, rhinovirus
[8–10].
The markedly reduced local inflammation in the airways after ad-
ministering NIH lays on its ability to inhibit the enzyme cyclooxygenase
and to markedly diminish reactive oxygen species (ROS). (Table 2)
These data are consistent with previous publications [16].
On the other hand, the mucolytic properties of NIH was detected in
healthy volunteers, and also in patients with COPD, a disease char-
acterized by significant chronic lung inflammation [17]; this response
shows the effectiveness of the compound in pathologies with re-
spiratory intervention and the broad spectrum demonstrated in the
treatment of conditions with similar characteristics.
From oral to inhaled and safe ibuprofen
The safety of inhaled NSAIDs has been previously demonstrated
[18], evaluating the response of inhaled sodium metaphosphate and
adenosine monophosphate in the absence of prostaglandins. They used
inhaled L-aspirin, indomethacin and sodium salicylate in asthmatic
patients. In this report, none of the inhaled NSAIDs changed FEV1 in
sensitive patients. In another study, Tamaoki et al., reported that in-
haled indomethacin decreased fluid and mucus in the respiratory tract
after 14 days of treatment without alterations in lung function. No
adverse effects were observed [19]. Other investigators found similar
results, inhalted AINES are safe [20]. Further confirmation of these
findings can be found in a recent Cochrane review [20]. Our laboratory
evaluated the effect of hypertonic ibuprofen in healthy adults and we
found an increase on FEV1/FVC ratio suggesting a bronchodilator ef-
fect, perhaps intrinsic to the anti-inflammatory effect (unpublished
data), during this experiment, serum ibuprofen increased from 0 to
1.09 ± 0.7 μg/ml and also the reactive oxygen species decreased from
1043 ± 252 to 441 ± 48 ΛU determined 30 min after the neb-
ulization, demonstrating in spite of the low serum concentration, this
presentation still maintains the anti-inflammatory property. We also
evaluated the effect of hypertonic ibuprofen using compassion and in
COPD patients, after 4 months of treatment, their FEV1, and the
walking test improved compared to basal, while the daily oxygen
Table 1
Effect of Na-Ibuprofenate on the vitro infective capacity of HSV, BVDV, VSV
and MV.
Virus Virus Characteristics Infective capacity title after Ibuprofen treatment
Family Genome Size (nM) TCID mL-l
HSV Herpes dsDNA 120–200 >6.9
BVDV Flavi ssRNA 50–70 >6.5
VSV Rhabdo ssRNA 70–170 >7.7
MV Paramyxo ssRNA 150–300 >5.0
Table 2
NIHM decreases reactive oxygen species (ROS) in human (expressed as ΛU), *
= p < 0.05.
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requirement was reduced. Another patient, with idiopathic pulmonary
fibrosis, after 1.5 years of treatment, he improved his FEV1, and the
ground glass opacity observed CT scan disappeared after 4 months of
treatment. Although these may be anecdotal findings, they may also
indicate the beneficial effects of inhaled ibuprofen.
The hypothesis
The new pathogen belonging to a family of viruses with a lipid
envelope in its structure. Using confocal microscopy and molecular
biology tools, [21], studied how the human coronavirus OC43 enters
the susceptible cell, visualizing that the virus uses endocytosis and that
the internalization process of vesicles that require actin, so it can play
an important role in early entry events during human coronavirus in-
fections [22]. Other investigators also showed the importance of actin
in the rapid spread of virus infection [26]. Furthermore, reorganization
of the actin filaments is a key step in lung inflammation induced by
systemic inflammatory responses caused by SARS-CoV-2 [23]. These
findings suggest that the interaction between actin proteins and S1 is
involved in the 2019-nCoV infection and pathogenesis. On the other
hand, the angiotensin-converting enzyme 2 (ACE2) is the functional
receptor for the spike glycoprotein of the SARS-CoV-2, therefore it
would play a crucial role in the entry of the virus into the cell to cause
the final infection [24]. Consequently, the possibility of interfering in
this interaction could represent a valid hypothesis for the development
of promising therapeutic and prevention strategies.
Nebulized hypertonic ibuprofen has antibiotic, viricidal and anti-
inflammatory effects that are expected to prevent viral replication in
the respiratory tract, minimize bacterial superinfections and reduce
inflammatory cytokines which appear to be the major problems in
COVID-19 [25]. Ibuprofen with the highest FDA performance side effect
profile, would be a promising adjunctive treatment for COVID-19 pa-
tients with moderate-severe respiratory symptoms. Additional research
is needed to further define its efficacy and safety in treating COVID-19.
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